A Study of CT-868 in Type 1 Diabetes Mellitus

NCT06062069 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obese
Type 1 Diabetes Mellitus

Interventions

DRUG: CT-868
DEVICE: CT-868 Pen Injector
DRUG: CT-868 Pen Injector, Placebo

Sponsor

Carmot Therapeutics, Inc.